nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA2C—attention deficit hyperactivity disorder	0.606	0.701	CbGaD
Apraclonidine—ADRA2A—attention deficit hyperactivity disorder	0.259	0.299	CbGaD
Apraclonidine—Brimonidine—ADRA2C—attention deficit hyperactivity disorder	0.00205	0.248	CrCbGaD
Apraclonidine—Tizanidine—ADRA2C—attention deficit hyperactivity disorder	0.00187	0.227	CrCbGaD
Apraclonidine—Lofexidine—ADRA2A—attention deficit hyperactivity disorder	0.00135	0.164	CrCbGaD
Apraclonidine—Clonidine—ADRA2C—attention deficit hyperactivity disorder	0.000913	0.111	CrCbGaD
Apraclonidine—Brimonidine—ADRA2A—attention deficit hyperactivity disorder	0.000873	0.106	CrCbGaD
Apraclonidine—Tizanidine—ADRA2A—attention deficit hyperactivity disorder	0.000798	0.0968	CrCbGaD
Apraclonidine—Clonidine—ADRA2A—attention deficit hyperactivity disorder	0.00039	0.0473	CrCbGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000128	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000127	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000125	0.000982	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000125	0.000982	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000124	0.000973	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000965	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000121	0.000957	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000121	0.000954	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000121	0.000954	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000121	0.000953	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000121	0.000953	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000121	0.00095	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000119	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000119	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000118	0.00093	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000116	0.000917	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000114	0.0009	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000113	0.000888	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000112	0.000886	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000112	0.000886	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.000885	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000112	0.000883	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000111	0.000874	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000111	0.000871	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00011	0.00087	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00011	0.000868	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00011	0.000868	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000109	0.000859	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000109	0.000858	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000107	0.000844	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000107	0.000841	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000106	0.000834	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000106	0.000833	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000105	0.000827	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000104	0.000823	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000104	0.00082	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000104	0.000817	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000104	0.000816	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000103	0.000814	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000103	0.000814	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000102	0.000802	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000101	0.000797	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	9.86e-05	0.000777	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	9.85e-05	0.000776	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	9.82e-05	0.000774	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.66e-05	0.000762	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	9.65e-05	0.000761	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	9.63e-05	0.000759	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	9.63e-05	0.000759	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	9.45e-05	0.000745	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.33e-05	0.000735	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.2e-05	0.000725	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.17e-05	0.000723	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	9.15e-05	0.000721	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.06e-05	0.000714	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.03e-05	0.000711	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.03e-05	0.000711	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	9.01e-05	0.00071	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.98e-05	0.000708	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	8.95e-05	0.000705	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	8.92e-05	0.000703	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.7e-05	0.000686	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	8.67e-05	0.000683	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.55e-05	0.000674	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.45e-05	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.45e-05	0.000666	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.44e-05	0.000665	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.42e-05	0.000664	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	8.42e-05	0.000663	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.39e-05	0.000661	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	8.39e-05	0.000661	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.36e-05	0.000658	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.19e-05	0.000645	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.13e-05	0.00064	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.99e-05	0.00063	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	7.98e-05	0.000629	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.89e-05	0.000622	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.89e-05	0.000622	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.89e-05	0.000622	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.87e-05	0.00062	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	7.84e-05	0.000618	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	7.65e-05	0.000603	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.65e-05	0.000603	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.51e-05	0.000592	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.36e-05	0.00058	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.36e-05	0.00058	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.35e-05	0.000579	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.34e-05	0.000578	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.33e-05	0.000578	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.24e-05	0.00057	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	7.14e-05	0.000563	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.11e-05	0.00056	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.98e-05	0.00055	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.98e-05	0.00055	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.9e-05	0.000544	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.9e-05	0.000544	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.87e-05	0.000542	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.84e-05	0.000539	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.82e-05	0.000538	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.82e-05	0.000537	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.76e-05	0.000533	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.68e-05	0.000527	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.6e-05	0.00052	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.43e-05	0.000506	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.41e-05	0.000505	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.41e-05	0.000505	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.34e-05	0.0005	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.25e-05	0.000492	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.21e-05	0.000489	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.01e-05	0.000474	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.97e-05	0.00047	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.91e-05	0.000466	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.84e-05	0.00046	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.75e-05	0.000453	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.67e-05	0.000447	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.58e-05	0.00044	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.51e-05	0.000434	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.49e-05	0.000433	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.46e-05	0.00043	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.37e-05	0.000423	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.3e-05	0.000418	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.15e-05	0.000406	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.1e-05	0.000402	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.1e-05	0.000402	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.08e-05	0.0004	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.96e-05	0.000391	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.94e-05	0.000389	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.92e-05	0.000387	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.84e-05	0.000381	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.83e-05	0.000381	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.77e-05	0.000376	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.74e-05	0.000374	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.74e-05	0.000374	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.74e-05	0.000374	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.69e-05	0.00037	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.63e-05	0.000365	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.63e-05	0.000365	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.61e-05	0.000363	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.59e-05	0.000362	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.52e-05	0.000356	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.52e-05	0.000356	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.5e-05	0.000355	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.48e-05	0.000353	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.47e-05	0.000352	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.46e-05	0.000351	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.46e-05	0.000351	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.45e-05	0.00035	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.43e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.39e-05	0.000346	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.36e-05	0.000343	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.34e-05	0.000342	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.31e-05	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.31e-05	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.18e-05	0.00033	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.17e-05	0.000329	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.15e-05	0.000327	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.15e-05	0.000327	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.14e-05	0.000327	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.1e-05	0.000323	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.05e-05	0.000319	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.05e-05	0.000319	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.04e-05	0.000318	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.03e-05	0.000318	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.02e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.95e-05	0.000311	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.95e-05	0.000311	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.9e-05	0.000307	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.87e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.85e-05	0.000304	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	3.81e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.81e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.77e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.77e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.76e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.75e-05	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	3.74e-05	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.73e-05	0.000294	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.67e-05	0.000289	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.65e-05	0.000287	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.63e-05	0.000286	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.62e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.6e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.58e-05	0.000282	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.54e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.5e-05	0.000276	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.48e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.39e-05	0.000267	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.37e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.35e-05	0.000264	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.3e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.29e-05	0.000259	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.13e-05	0.000247	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.11e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	3.09e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.09e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.06e-05	0.000241	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.04e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	3.04e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.93e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.91e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.9e-05	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.83e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.83e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.74e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.74e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.72e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.64e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.64e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	2.61e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.59e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.56e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.54e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.54e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.54e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.47e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.46e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	2.44e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.42e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.39e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.39e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.39e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.36e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.31e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	2.31e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	2.29e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.23e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.22e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.22e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.15e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.15e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.12e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.09e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.07e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.98e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.95e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.94e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.87e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.86e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.81e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.67e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.56e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.36e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.27e-05	9.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	9.89e-06	7.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.85e-06	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.27e-06	6.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	8.03e-06	6.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.23e-06	5.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.72e-06	5.29e-05	CbGpPWpGaD
